Logo image of MNKD

MANNKIND CORP (MNKD) Stock Price, Quote, News and Overview

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

5  +0.05 (+1.01%)

After market: 5 0 (0%)

MNKD Quote, Performance and Key Statistics

MANNKIND CORP

NASDAQ:MNKD (5/2/2025, 8:10:51 PM)

After market: 5 0 (0%)

5

+0.05 (+1.01%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High7.63
52 Week Low4.17
Market Cap1.52B
Shares303.86M
Float298.89M
Yearly DividendN/A
Dividend YieldN/A
PE62.5
Fwd PE26.81
Earnings (Next)05-07 2025-05-07/amc
IPO07-28 2004-07-28


MNKD short term performance overview.The bars show the price performance of MNKD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

MNKD long term performance overview.The bars show the price performance of MNKD in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15

The current stock price of MNKD is 5 USD. In the past month the price increased by 2.46%. In the past year, price increased by 13.9%.

MANNKIND CORP / MNKD Daily stock chart

MNKD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About MNKD

Company Profile

MNKD logo image MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 407 full-time employees. The company went IPO on 2004-07-28. The firm's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.

Company Info

MANNKIND CORP

1 Casper Street

Danbury CONNECTICUT 91362 US

CEO: Michael E. Castagna

Employees: 413

Company Website: https://mannkindcorp.com/

Investor Relations: https://investors.mannkindcorp.com

Phone: 18186615000

MANNKIND CORP / MNKD FAQ

What is the stock price of MANNKIND CORP today?

The current stock price of MNKD is 5 USD. The price increased by 1.01% in the last trading session.


What is the ticker symbol for MANNKIND CORP stock?

The exchange symbol of MANNKIND CORP is MNKD and it is listed on the Nasdaq exchange.


On which exchange is MNKD stock listed?

MNKD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MANNKIND CORP stock?

12 analysts have analysed MNKD and the average price target is 10.49 USD. This implies a price increase of 109.83% is expected in the next year compared to the current price of 5. Check the MANNKIND CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MANNKIND CORP worth?

MANNKIND CORP (MNKD) has a market capitalization of 1.52B USD. This makes MNKD a Small Cap stock.


How many employees does MANNKIND CORP have?

MANNKIND CORP (MNKD) currently has 413 employees.


What are the support and resistance levels for MANNKIND CORP (MNKD) stock?

MANNKIND CORP (MNKD) has a support level at 4.53 and a resistance level at 5. Check the full technical report for a detailed analysis of MNKD support and resistance levels.


Is MANNKIND CORP (MNKD) expected to grow?

The Revenue of MANNKIND CORP (MNKD) is expected to grow by 13.64% in the next year. Check the estimates tab for more information on the MNKD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MANNKIND CORP (MNKD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MANNKIND CORP (MNKD) stock pay dividends?

MNKD does not pay a dividend.


When does MANNKIND CORP (MNKD) report earnings?

MANNKIND CORP (MNKD) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of MANNKIND CORP (MNKD)?

The PE ratio for MANNKIND CORP (MNKD) is 62.5. This is based on the reported non-GAAP earnings per share of 0.08 and the current share price of 5 USD. Check the full fundamental report for a full analysis of the valuation metrics for MNKD.


What is the Short Interest ratio of MANNKIND CORP (MNKD) stock?

The outstanding short interest for MANNKIND CORP (MNKD) is 8.79% of its float. Check the ownership tab for more information on the MNKD short interest.


MNKD Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD turns out to be only a medium performer in the overall market: it outperformed 56.44% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MNKD Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to MNKD. Both the profitability and the financial health of MNKD get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MNKD Financial Highlights

Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.08. The EPS increased by 260% compared to the year before.


Industry RankSector Rank
PM (TTM) 9.66%
ROA 7%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%390.38%
Sales Q2Q%31.3%
EPS 1Y (TTM)260%
Revenue 1Y (TTM)43.49%

MNKD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to MNKD. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 133.15% and a revenue growth 13.64% for MNKD


Ownership
Inst Owners61.62%
Ins Owners1.42%
Short Float %8.79%
Short Ratio12.42
Analysts
Analysts86.67
Price Target10.49 (109.8%)
EPS Next Y133.15%
Revenue Next Year13.64%